Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cycloserine rTMS Plasticity Enhancement
NCT03432689Phase 1Completed
- Sponsor
- University of Calgary
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing D-Cycloserine with Placebo (2 arms). Primary endpoint: Motor Evoked Potential amplitude. Started Aug 2018; status: completed.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03432689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432689.